On November 2, 2010, Hoffmann-La Roche Ltd., in consultation with Health Canada strengthened their warning regarding QT/PR prolongation and the need for ECG monitoring with ritonavir-boosted Invirase.
For more information: Click here to view the Health Canada advisory